Over the last 7 days, the South Korean market has risen 4.1%, driven by gains of 8.2% in the Information Technology sector, and in the last year, it has climbed 5.1%. With earnings forecast to grow by 28% annually, identifying high-growth tech stocks that align with these robust market conditions can be crucial for investors looking to capitalize on this momentum.
Top 10 High Growth Tech Companies In South Korea
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
ALTEOGEN |
48.67% |
72.95% |
★★★★★★ |
|
IMLtd |
20.76% |
106.30% |
★★★★★★ |
|
Bioneer |
22.49% |
89.69% |
★★★★★★ |
|
NEXON Games |
31.70% |
66.31% |
★★★★★★ |
|
Seojin SystemLtd |
34.20% |
58.67% |
★★★★★★ |
|
EuBiologics |
28.05% |
93.39% |
★★★★★★ |
|
Devsisters |
26.11% |
65.92% |
★★★★★★ |
|
AmosenseLtd |
24.29% |
55.45% |
★★★★★★ |
|
Park Systems |
22.50% |
37.52% |
★★★★★★ |
|
UTI |
103.56% |
122.67% |
★★★★★★ |
Click here to see the full list of 48 stocks from our KRX High Growth Tech and AI Stocks screener.
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medy-Tox Inc. is a biopharmaceutical company based in South Korea with a market cap of ₩1.38 billion.
Operations: The company primarily generates revenue from its biotechnology segment, amounting to ₩233.03 billion.
Medy-Tox’s R&D expenditure underscores its commitment to innovation, with ₩29.4B allocated last year, representing a significant 11.3% of revenue. Despite a volatile share price and lower profit margins at 0.8%, the company is poised for substantial growth with earnings projected to increase by 60.7% annually over the next three years, outpacing the Korean market’s average of 28.4%. This focus on biopharmaceutical advancements positions Medy-Tox favorably within South Korea’s competitive tech landscape.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Seegene, Inc. manufactures and sells molecular diagnostics products worldwide, with a market cap of ₩1.59 trillion.
Operations: The company primarily generates revenue through the sale of diagnostic kits and equipment, amounting to ₩367.27 billion.
Seegene’s focus on innovation is evident from its robust R&D expenditure, which amounted to ₩29.4B last year, accounting for 11.3% of its revenue. Despite a volatile share price over the past three months and current unprofitability, the company’s earnings are forecasted to grow at an impressive 62.6% annually over the next three years, signaling a strong potential for future profitability. The recent extension of its share buyback plan until July 2025 further underscores Seegene’s commitment to enhancing shareholder value in South Korea’s competitive tech landscape.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pearl Abyss Corp. engages in software development for games and has a market cap of ₩2.73 trillion.
Operations: Pearl Abyss Corp. generates revenue primarily from game sales, amounting to ₩325.80 billion. The company focuses on developing software for games, contributing significantly to its financial performance.
Pearl Abyss, known for its gaming innovations, is set to see a revenue growth of 23.2% annually, outpacing the South Korean market’s 10.7%. Their earnings are forecasted to surge by 58.1% per year, driven by recent profitability and strategic expansions in the entertainment sector. The company’s R&D expenses amounted to ₩29.6B last year, emphasizing their commitment to innovation and quality content creation. Recent earnings calls indicate robust performance with significant one-off gains impacting financial results positively.
Turning Ideas Into Actions
Curious About Other Options?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A086900 KOSDAQ:A096530 and KOSDAQ:A263750.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
